Revenue segments as reported by the company.

Net product sales

Alliance and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, selling and administrative

Research and development

IPRD charge - MyoKardia acquisition

Amortization of acquired intangible assets

Other (income)/ expense, net

Acquired IPRD

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bristol-Myers

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bristol-Myers reports robust 2022 performance and outlines growth strategies

Bristol-Myers Squibb delivered strong financial performance in 2022, with revenue growth and key product successes driving sales to $46 billion.
The company's strategic focus on portfolio expansion, market access enhancement, and operational efficiency positions it for continued growth and value creation.
Challenges around market access, legislative impacts, and expense management require strategic attention, while opportunities in product development and market expansion offer avenues for future growth.

Bristol-Myers reports robust Q1 earnings, eyes growth amid challenges

Bristol-Myers' Q1 2023 performance reflects strong sales growth and a focus on innovation, with significant progress in pipeline development and new product launches.
While facing challenges from generic competition and operational issues, the company is well-positioned to capitalize on industry advancements and strategic opportunities for growth.
By reaffirming guidance, emphasizing strategic alignment, and pursuing new therapies, Bristol-Myers demonstrates resilience and a commitment to long-term success in the pharmaceutical market.

Bristol-Myers reports robust Q2 sales and strategic growth initiatives

Bristol-Myers' Q2 performance showcased strong sales driven by new product growth and key product successes like Opdivo and Reblozyl.
While facing challenges with certain products and revenue guidance changes, the company remains confident in its financial commitments and growth outlook.
Opportunities lie in capacity ramp-up for key products, conversion strategies for patient assistance programs, and upcoming R&D insights.
Overall, Bristol-Myers' performance, strengths, and opportunities position the company for continued growth and success in the pharmaceutical market.

Bristol-Myers reports robust Q3 performance, eyes growth opportunities

Bristol-Myers Squibb's Q3 earnings call highlighted strong performance, strategic initiatives for growth, and confidence in future prospects. Despite challenges in product performance and reimbursement, the company is optimistic about market improvements and growth opportunities. Executives are focused on driving sustainable long-term growth and expanding their product portfolio.

Bristol-Myers reports robust Q4 earnings, eyes growth through strategic initiatives

Bristol-Myers' Q4 2023 showcased strong financial performance, strategic advancements, and a focus on growth drivers like Opdivo and new launches.
Despite challenges in negotiations and market dynamics, Bristol-Myers remains poised for growth through its robust product portfolio and business development strategies.
The company's emphasis on innovation, commercial execution, and clinical progress positions Bristol-Myers for sustained growth and market leadership in the pharmaceutical industry.

Bristol-Myers meets Q1 expectations, focuses on growth opportunities

Bristol-Myers Squibb's Q1 performance met expectations with strong sales growth driven by key brands and strategic acquisitions.
Despite challenges in operating expenses and interest costs impacting income, the focus on efficiency and cost savings remains a priority.
The company's strengths lie in robust sales growth of key brands, promising pipeline advancements, and strategic capital allocation plans.
Opportunities in expanding indications, new trials, and market launches position Bristol-Myers for long-term growth and competitive advantage.

Bristol-Myers reports strong Q2 performance, bullish on pipeline growth

Bristol-Myers (BMY) showcased a robust Q2 performance, emphasizing pipeline advancements and strategic capital allocation for growth and returns.
The company is confident in navigating pricing changes and improving access dynamics for key products, while focusing on transformative medicines and operational excellence.
With a positive outlook for the year, Bristol-Myers is poised to leverage opportunities in oncology, pipeline advancements, and expanding indications for key assets.

Bristol-Myers (BMY) reports strong Q3 sales and pipeline progress

Bristol-Myers Squibb (BMY) showcased robust performance with strong sales growth and positive clinical data for pipeline programs.
The company's strategic strengths lie in operational excellence, capital allocation, and commitment to sustainable growth and innovation.
Challenges include market dynamics, competition in heart failure drugs, and translating clinical data into successful drug programs.
Opportunities abound in the growing heart failure drugs market, upcoming trial data readouts, and continued focus on portfolio growth and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb and Ted Danson Empower Those with Plaque Psoriasis to Take Action in “SO, Have You Found It?” Campaign.

Bristol Myers Squibb and Ted Danson Empower Those with Plaque Psoriasis to Take Action in “SO, Have You Found It?” Campaign

Bristol Myers' (BMY) Abecma gets eight out of 11 votes from the FDA's ODAC for patients with triple-class exposed relapsed or refractory multiple myeloma in earlier lines of therapy.

Bristol Myers' (BMY) Abecma Gets ODAC Votes for Label Expansion

PureTech Health PLC

BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company, today announced the completed acquisition of its Founded Entity, Karuna Therapeutics, Inc. ("Karuna”), by Bristol Myers Squibb (NYSE: BMY) (“BMS”), which has acquired all outstanding common stock of Karuna for $330.00 per share, for a total equity value of approximately $14 billion. "This acquisition recognizes the enormous potential of KarXT to help mi.

Bristol Myers Squibb Completes Acquisition of PureTech's Founded Entity Karuna Therapeutics for $14 Billion

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that it has successfully completed its acquisition of Karuna Therapeutics, Inc. (“Karuna”). With the acquisition's completion, Karuna shares have ceased trading on the Nasdaq Global Select Market and Karuna is now a wholly owned subsidiary of Bristol Myers Squibb (“BMS”). “We are excited to expand our neuroscience portfolio as we welcome Karuna to Bristol Myers Squibb,” said Chris Boerner, Ph.D., Chief Executive.

Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics, Strengthening Neuroscience Portfolio

PRINCETON, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BMY #Abecma--FDA Advisory Committee Votes in Favor of BMS' and 2seventy bio's Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy.

FDA Advisory Committee Votes in Favor of Bristol Myers Squibb's and 2seventy bio's Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy

Advisers to the U.S. Food and Drug Administration on Friday voted in favor of allowing the use of Bristol Myers Squibb's cell therapy as an earlier treatment for a type of blood cancer.

US FDA panel votes in favor of expanded use of Bristol Myers' CAR-T therapy

Bristol Myers (BMY) obtains FDA approval for the label expansion of CAR T cell therapy, Breyanzi, for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

Bristol Myers (BMY) Gets FDA Nod for Breyanzi's Label Expansion

Bristol Myers Squibb Co.'s cell therapy Breyanzi won U.S. Food and Drug Administration approval late Thursday for treatment of a common type of leukemia — a decision that comes just ahead of an FDA meeting Friday that will scrutinize the risks and benefits of two other cell therapies.

Bristol Myers Squibb cell therapy gets FDA green light to treat common type of leukemia

The U.S. Food and Drug Administration on Thursday expanded the use of Bristol Myers Squibb's cell therapy, Breyanzi, for a type of slow-growing blood cancer, marking the second approval for the treatment.

US FDA expands use of Bristol Myers' cancer therapy

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Breyanzi--U.S. FDA Approves Bristol Myers Squibb's Breyanzi® as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory CLL or SLL.

U.S. FDA Approves Bristol Myers Squibb's Breyanzi® as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Bristol Myers Squibb (BMY) concluded the recent trading session at $52.49, signifying a -0.3% move from its prior day's close.

Bristol Myers Squibb (BMY) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Air Products and Chemicals

Best Buy

Evergy Inc

Hershey

Alliant Energy

Morgan Stanley

NextEra Energy

WEC Energy Group

Essential Utilities

Xcel Energy

The Efficient Market Hypothesis states that the stock market is efficiently priced, and therefore it is impossible to consistently generate alpha.

Get Paid To Wait: 13 Potential Dividend Opportunities

Bristol-Myers Squibb Company (NYSE:BMY) Barclays 26th Annual Global Healthcare Conference March 14, 2024 8:30 AM ET

Bristol-Myers Squibb Company (BMY) Barclays 26th Annual Global Healthcare Conference (Transcript)

Celgene

Bristol-Myers Squibb Company (BMY) Management Presents at Leerink Partners Global Biopharma Conference 2024 Conference (Transcript)

Johnson & Johnson

The U.S. Food and Drug Administration's staff reviewers on Wednesday raised safety concerns over the use of Johnson & Johnson's and Bristol-Myers Squibb's cancer therapies as earlier treatments for blood cancer patients.

US FDA staff flag safety concerns from J&J, Bristol's CAR-T therapies

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Report Results for First Quarter 2024 on April 25, 2024.

Bristol Myers Squibb to Report Results for First Quarter 2024 on April 25, 2024

Comerica

Dominion Energy

Altria

Sponsored: Tips for Investing A financial advisor can help you understand the advantages and disadvantages of investment properties.

5 Top Dividend Stocks Passive Income Investors Should Buy in March

Archer-Daniels-Midland Company

Enbridge

Microsoft

Visa

This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering large discounts to their historical norms.

5 Relatively Secure And Cheap Dividend Stocks To Invest In - March 2024

Bristol-Myers Squibb has returned to sales growth after a period of declining sales, signaling a turnaround ahead. The biopharma continues to be hit by key drugs facing LOEs, but new drugs and acquisitions show promising sales ramps. The stock trades at ~7x 2025 EPS targets with more upside as dilutive deals in 2024 start to pay off.

Bristol-Myers Squibb: Finally Trending Up

Bristol-Myers Squibb might have seen a price decline over the past year, but it now boasts of a superior dividend yield and competitive P/E ratio compared to peers. After a revenue setback on the patent erosion of its cancer treatment drug, it's now seeing progress in new products and some big existing ones. Its recent acquisitions might be small, but they do have significant growth potential, with two of the three already being revenue generating.

Bristol-Myers Squibb: Turnaround Expected

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CheckMate--U.S. FDA Approves Opdivo in Combination with Cisplatin and Gemcitabine, for First-Line Treatment.

U.S. Food and Drug Administration Approves Opdivo® (nivolumab), in Combination with Cisplatin and Gemcitabine, for First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma

Bristol-Myers Squibb's stock has gained momentum after a difficult 2023, suggesting a positive outlook for the company.

Bristol-Myers Squibb: Compelling Value From The New Products Portfolio And 4.5% Yield

Disney

Intel

Pfizer

PayPal

If you're searching for must-have stocks for wealth, look no further. In investing, identifying the right stocks leads to a fear of missing out.

Millionaire's Blueprint: 7 Must-Have Stocks for Your Road to Wealthy Town

Bristol-Myers Squibb Company (NYSE:BMY ) 44th Annual TD Cowen Healthcare Conference March 4, 2024 9:50 AM ET Company Participants Roland Chen - SVP and Head, Cardiovascular and Neuroscience Development, Global Drug Development Conference Call Participants Steve Scala - TD Cowen Steve Scala Well, good morning once again. We're delighted to have Bristol-Myers Squibb here at the Cowen 44th Annual Healthcare Conference, representing the company is Roland Chen, who's Senior Vice President and Head of Immunology, Cardiology, or Cardiovascular and Neuroscience Development.

Bristol-Myers Squibb Company (BMY) 44th Annual TD Cowen Healthcare Conference (Transcript)

British American Tobacco

Kinder Morgan

AT&T

2022 was a dreadful year for investors, with the S&P 500 down almost 20% and the Nasdaq lower by a stunning 33%.

News for Bristol-Myers Stock (BMY)